GoldenGolden
Advanced Search
Altimmune

Altimmune

Altimmune is a therapeutics, treatment, and vaccine development company that looks to find response and prevention solutions

About

Altimmune is a therapeutics, treatment, and vaccine development company that looks to find response and prevention solutions. The company was founded by De-chu Christopher Tang in 1997, in Gaithersburg, Maryland, United States.

The company is known for their programs that deal with peptide-based therapeutics for liver diseases, peptide-conjugated immuno-stimulants for cancer, and intranasal vaccines for Anthrax and Influenza.

COVID-19 Treatments and Solutions

With the outbreak of COVID-19, Altimmune announced the development of a single-dose, intranasal vaccine against the virus which was caused by the SARS-CoV-2 virus. The vaccine design and synthesis has been advanced to animal testing and manufacturing. A Phase 2 clinical study with NasoVAX demonstrated the ability the delivery system was durable and stimulated a broad immune response against the influenza virus. They believe the same delivery system would work for the vaccine in development for COVID-19.

Timeline

Funding rounds

Products

Patents

Products

People

Name
Role
LinkedIn

Bertrand Georges

CTO

Jose Ochoa

CBO

Scot Roberts

CSO

Scott Harris

CMO

Vipin Garg

President, CEO

Further reading

Title
Author
Link
Type
Date

Altimmune

jpoly4

Web

November 15, 2019

Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine - Altimmune

Web

Coronavirus outbreak: Top coronavirus drugs and vaccines in development

Web

March 6, 2020

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Altimmune

Vipin Garg

Gaithersburg, Maryland, United States

Therapeutics, treatments, and vaccines for diseases

News

Title
Author
Date
Publisher
Description
Vanessa Doctor, RN
June 30, 2021
BioSpace
The company said it would halt activities and focus its resources and time on liver and obesity research following "disappointing" results of its intranasal COVID-19 vaccine.
Kyle LaHucik
June 29, 2021
FierceBiotech
After not-so-promising results from a phase 1 trial, Altimmune is scrapping its COVID-19 vaccine nasal spray candidate and stopping further enrollment in a COVID-19 therapeutic program. The news comes just as the Delta variant picks up steam around the world.
BioSpace
May 26, 2021
BioSpace
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced new results from a preclinical study demonstrating the ability of its AdCOVID vaccine candidate to neutralize the rapidly emerging SARS-CoV-2 B.1.351 variant of concern that originated in South Africa.
BioSpace
May 10, 2021
BioSpace
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced positive results from a preclinical study of AdCOVID in a SARS-CoV-2 challenge model of infection.
Aylin Woodward and Allison DeAngelis
March 5, 2021
Business Insider
A company called Altimmune is working on a nasal-spray version of a COVID-19 vaccine. The technology could stem the virus' spread better than shots.
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.